Synonyms: Spedra® | Stendra® | TA-1790
avanafil is an approved drug (FDA (2012), EMA (2013))
Compound class:
Synthetic organic
Comment: Avanafil is a phosphodiesterase type 5 inhibitor.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖View more information in the IUPHAR Pharmacology Education Project: avanafil |
|
Bioactivity Comments |
Most of the research into the pharmacology of this drug appears to have been carried out in dogs. We have been unable to find publicly available bioactivity for avanafil in relation to human PDE5 to substantiate its clinical MMOA. Therefore, we have not tagged a primary target for this drug. |